Drug intelligence / Profile preview

NLY12

Development stage: Unknown
Lead developer: D&D Pharmatech
Modality: Peptides
Administration: Subcutaneous

Overview

NLY12 is an injectable peptide-based drug candidate developed by D&D Pharmatech. It functions as a Glucagon-like peptide 1 receptor (GLP-1R) agonist. The drug is specifically designed for the treatment of obesity, leveraging the well-established mechanism of GLP-1 to regulate appetite, slow gastric emptying, and improve glycemic control. Unlike D&D Pharmatech's ORALINK-based oral candidates, NLY12 is formulated for injectable administration. It is currently in Phase 1 clinical development.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on NLY12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NLY12.

Explore the full profile